Uncategorized

TauRx’s Hydromethylthionine Mesylate (HMTM) Demonstrates Significant Reduction in Neurodegeneration in Alzheimer’s Disease (AD)

TauRx Pharmaceuticals Ltd. announced results from a prespecified analysis of the Phase 3 LUCIDITY trial that measured the impact of HMTM on neurofilament light chain, an established biomarker for brain neurodegeneration.

TauRx’s Hydromethylthionine Mesylate (HMTM) Demonstrates Significant Reduction in Neurodegeneration in Alzheimer’s Disease (AD) Read More »

The Committee to Restore Nymox Shareholder Value Soundly Rebuts Injurious Allegations Made by Nymox Pharmaceutical Corp Current Management

The Committee to Restore Nymox Shareholder Value, LLC, with a goal to recover shareholder value in NYMOX PHARMACEUTICAL CORP by reestablishing a proposed partnership with a highly respected, global specialty pharmacy and healthcare solutions company, resolutely refutes all allegations made in a press release by current Nymox leadership.

The Committee to Restore Nymox Shareholder Value Soundly Rebuts Injurious Allegations Made by Nymox Pharmaceutical Corp Current Management Read More »

Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023

Acumen Pharmaceuticals, Inc. presented positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AβO targeting antibody therapy in early AD, at the Alzheimer’s Association International Conference 2023, taking place in Amsterdam and online from July 16-20, 2023.

Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023 Read More »

Scroll to Top